Jakub Baran – CEO of Vita 34 AG
Jakub Baran graduated in 1995 from the Wrocław University of Technology as a Master of Science and Engineer in Electronics, majoring in Telecommunications – Digital Signal Processing. He started his professional career at Hewlett-Packard as Staff Engineer and then later as VAB Developer, PC Sales Representative, Senior Account Manager. He joined IBM in 2003 as Sales Director for Telecommunication Market. While working in the IT industry, Jakub has been very successful in sales always meeting or exceeding the number of goals. In 2005 he decided to leave IBM to join PBKM board – the company established in 2002 where he was one of five founders. At PBKM he was initially responsible for sales, operations, finance and business development as well. In 2006 Jakub Baran initiated international expansion of PBKM. He was responsible personally for ~20 successful M&A-nature transactions in: Hungary, Spain, Romania, Poland, Turkey, Latvia, Switzerland, Czech Rep., Slovakia, Portugal and the UK. In the meantime in 2009 he was appointed as CEO of PBKM. He led successful IPO of PBKM at WSE in 2015. Under his management PBKM (operating under umbrella of FamiCord Group) reached position no 1 in Europe with ca 40% market share and no 4 in the world in family stem cell banking sector. During his career at PBKM Jakub gather a lot of expertise in various areas like building international capital group, creation and implementation of strategy, preparation and execution of company budgets, deep experience in mergers and acquisitions, practical knowledge of law in the area of commercial and investment agreements, practical knowledge of financial reporting and experience in managing international teams/companies of 500+ people. Jakub was an initiator and spiritus movens of the merger between PBKM and Vita34. Jakub finished couple of dozens of various professional trainings across Europe (including programs organized by INSEAD and IESE). He is also co-author of a dozen of articles on stem cells applications and technology. Privately a fan of SF literature, strategic games and economy. He stays in informal partnership and has one child.
Andreas Schafhirt – CFO of Vita 34 AG
Andreas Schafhirt, born in 1962, was appointed CFO of Vita 34 in August 2021.
He studied economics and Industrial Engineering at the Technical University of Berlin and graduated with a degree in economics. Subsequently, Mr Schafhirt started at Berliner Industriebank AG, where he was involved, among other things, with the implementation of credit programmes for the promotion of the economy in eastern Germany. He then moved to the stationery industry and took over the management and further development of the accounting, controlling and finance department at Herlitz AG. In 2000, he became CFO of the Protective & Decorative Finishes Division at packaging manufacturer Impress B.V., based in Amsterdam and Paris, where he was in charge of the post-merger integration of two parts of the company. His career then took him back to the office supplies industry as CFO of Biella-Neher AG in Switzerland. Milestones were the IPO in 2006, numerous M&A transactions and restructurings as well as the sale of the company in a structured bidding process with subsequent integration.
Tomasz Baran – CCO of Vita 34 AG
In 1997, Tomasz Baran completed medical education with MD title from Medical University in Lublin, Poland. Since then he has been working on several positions in pharma industry in Poland. His duties covered sales, marketing, business development and pharmacovigilance. In 2008, Tomasz completed Executive MBA programme by Quebec University in Montreal. During 13 years of work for domestic and international companies (Pliva, AstraZeneca, Stiefel and GSK) he has gained an expertise in several therapeutic areas – including oncology, cardiology, dermatology and aesthetic medicine. In 2010, he joined Polski Bank Komórek Macierzystych S.A. (PBKM) in a role of Sales &Marketing Director for domestic market. Then the role expanded to cover also international markets, where PBKM operates under FamiCord brand. In 2012, Tomasz joined the Management Board, and since 2020 he serves as Executive Vice-president. In recent years, he attended dedicated international executive training programmes done by IESE. He regularly attends and contributes as speaker on stem cell conferences in Europe and in the US. Additionally to developing of family cord blood bank activity Tomasz contributed to strategic projects of FamiCord group, such us stem cell based Advanced Therapy Product (ATMP) manufacturing and novel CAR-T technology in licensing (as CEO of daughter company – FamiCordTx).